Saturday, July 11, 2026
🇺🇸 FDA

Drug profile · INN

astx727

astx727 is an FDA-listed pharmaceutical active ingredient.

NMPA: clinical trials
Patents linked 0
Pipeline programs 6
News articles 0
Drug details — astx727
Class
—
Route
—
Patents
0
Programs
6
Data quality
0.70
← All drugs Search patents Pipeline programs Drug news hub Event calendar

Quick answer

astx727 is an FDA-listed pharmaceutical active ingredient.

Key facts

INN astx727

Approval history

Authority Status Date
NMPA clinical trials —

Pipeline programs

Browse pipeline
  1. ASTX727 Phase 2 · Taiho Pharma Canada · Acute myeloid lymphoma (AML), myelodysplastic syndrome (MDS)
  2. ASTX727-07 Phase 2 · Taiho Pharma Canada · Acute Myeloid Leukemia (AML)
  3. NIBIT-ML-1 Phase 2 · Telethon Foundation · MM and NSCLC patients resistant to anti-PD-1/PD-L1 therapy
  4. ASTX727-03 Phase 1 · Taiho Pharma Canada · Myelodysplastic Syndromes (MDS)
  5. ASTX727-17 Phase 1 · Taiho Pharma Canada · Acute myeloid lymphoma (AML), myelodysplastic syndrome (MDS)
  6. ASTX727-18 Phase 1 · Taiho Pharma Canada · Solid tumor, Acute myeloid lymphoma (AML), Myelodysplastic s

Frequently asked questions

What is astx727?

astx727 is an FDA-listed pharmaceutical active ingredient.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.